ProNai Therapeutics

Michigan Tech Startups Get Funding From GR's Grand AngelsThe Grand Rapids private investor group Grand Angels announced its latest funding commitments to a group of Michigan startups.
ProNAi Raises $12M Series C Financing To Expand Cancer StudiesThe cancer drug developer ProNAi Therapeutics Inc. Monday announced the closing of a Series C preferred financing round of more than $12 million with existing and new investors.
ProNai Therapeutics Reports Anti-Tumor Activity From Drug CanddiateProNai Therapeutics Inc. reported promising new results Sunday from an ongoing Phase II study of its lead drug candidate at the 55th Annual Meeting of the American Society for Hematology in New Orleans, La.
ProNAi To Present Phase II Clinical Data For New Cancer DrugProNAi Therapeutics Inc., a developer of drugs that target cancer by interfering with cancer cells' DNA, announced that data from its ongoing Phase II clinical study of its drug candidate PNT2258 will be presented at the 55th Annual Meeting of the American Society of Hematology in New Orleans Dec. 7-10.
ProNAi Presents Cancer Drug Results, Expands Management TeamProNAi Therapeutics Inc., a cancer drug development company, said last week that it had concluded its initial human clinical trial of PNT2258, a new type of nucleic acid drug.
MVCA Programs to Attract Investment, Entrepreneur Talent Gaining Traction The Michigan Venture Capital Association’s programs to develop the state’s investment community are helping venture capitalists and their portfolio companies attract and retain top talent.